Juliette Mb Hukin

List of Publications by Year
in descending order

105	4,590	109321 35	106344 65
papers	citations	h-index	g-index

109	109	109	5500
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nature Genetics, 2014, 46, 451-456.	21.4	525
2	Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma. Journal of Clinical Oncology, 2012, 30, 1358-1363.	1.6	198
3	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell, 2016, 30, 891-908.	16.8	191
4	Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathologica, 2017, 134, 705-714.	7.7	168
5	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology, 2016, 34, 2468-2477.	1.6	160
6	Phase II Weekly Vinblastine for Chemotherapy-NaÃ¯ve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study. Journal of Clinical Oncology, 2016, 34, 3537-3543.	1.6	157
7	Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma. Journal of Clinical Oncology, 2019, 37, 974-983.	1.6	154
8	Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. Lancet Oncology, The, 2015, 16, 569-582.	10.7	147
9	Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nature Medicine, 2020, 26, 720-731.	30.7	141
10	Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): Report of the Head Start I and II experience. Pediatric Blood and Cancer, 2008, 50, 312-318.	1.5	125
11	Treatment of Intracranial Ependymoma by Surgery Alone. Pediatric Neurosurgery, 1998, 29, 40-45.	0.7	117
12	Clinical and neuroanatomical predictors of cerebellar mutism syndrome. Neuro-Oncology, 2012, 14, 1294-1303.	1.2	112
13	Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. Pediatric Blood and Cancer, 2007, 49, 34-40.	1.5	104
14	Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma. Acta Neuropathologica Communications, 2016, 4, 93.	5.2	100
15	Cerebelloâ€“thalamoâ€“cerebral connections in pediatric brain tumor patients: Impact on working memory. NeuroImage, 2011, 56, 2238-2248.	4.2	99
16	A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01. BMC Cancer, 2019, 19, 1250.	2.6	93
17	Intratumoral Therapy with Bleomycin for Cystic Craniopharyngiomas in Children. Pediatric Neurosurgery, 2000, 33, 211-218.	0.7	92
18	Intracystic bleomycin therapy for craniopharyngioma in children. Cancer, 2007, 109, 2124-2131.	4.1	89

#	Article	IF	Citations
19	Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica, 2018, 136, 227-237.	7.7	86
20	Carboplatin hypersensitivity reaction in pediatric patients with lowâ€grade glioma. Cancer, 2008, 112, 892-899.	4.1	77
21	Intracystic treatments for craniopharyngioma. Neurosurgical Focus, 2010, 28, E13.	2.3	66
22	Clinical Manifestations of Childhood Ependymoma:A Multitude of Syndromes. Pediatric Neurosurgery, 1998, 28, 49-55.	0.7	65
23	Late mortality in pediatric patients with craniopharyngioma. Journal of Neuro-Oncology, 2010, 100, 105-111.	2.9	63
24	Medulloblastoma in the second decade of life: A specific group with respect to toxicity and management. Cancer, 2005, 103, 1874-1880.	4.1	61
25	Changes to Memory Structures in Children Treated for Posterior Fossa Tumors. Journal of the International Neuropsychological Society, 2014, 20, 168-180.	1.8	59
26	Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on â€œHead Startâ€•III: a multi-institutional, prospective clinical trial. Neuro-Oncology, 2020, 22, 1862-1872.	1.2	57
27	A randomized control intervention trial to improve social skills and quality of life in pediatric brain tumor survivors. Psycho-Oncology, 2018, 27, 91-98.	2.3	54
28	Reirradiation in patients with diffuse intrinsic pontine gliomas: The Canadian experience. Pediatric Blood and Cancer, 2018, 65, e26988.	1.5	51
29	Longitudinal Outcomes in the 2014 Acute Flaccid Paralysis Cluster in Canada. Journal of Child Neurology, 2017, 32, 301-307.	1.4	50
30	Leptomeningeal dissemination in children with progressive low-grade neuroepithelial tumors. Neuro-Oncology, 2002, 4, 253-260.	1.2	48
31	Late effects in survivors of childhood CNS tumors treated on Head Start I and II protocols. Pediatric Blood and Cancer, 2014, 61, 1644-1672.	1.5	46
32	A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma. European Journal of Cancer, 2010, 46, 3271-3279.	2.8	43
33	Atypical teratoid rhabdoid tumor in the first year of life: the Canadian ATRT registry experience and review of the literature. Journal of Neuro-Oncology, 2017, 132, 155-162.	2.9	43
34	White matter and information processing speed following treatment with cranial-spinal radiation for pediatric brain tumor.. Neuropsychology, 2016, 30, 425-438.	1.3	42
35	Outcome of secondary high-grade glioma in children previously treated for a malignant condition: A study of the Canadian Pediatric Brain Tumour Consortium. Radiotherapy and Oncology, 2006, 81, 33-38.	0.6	41
36	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 807-821.	1.6	40

#	Article	IF	Citations
37	Intracranial Germ Cell Tumors in Adolescents and Young Adults: A 40-Year Multi-Institutional Review of Outcomes. International Journal of Radiation Oncology Biology Physics, 2020, 106, 269-278.	0.8	38
38	Pediatric thalamic tumors in the MRI era: a Canadian perspective. Child's Nervous System, 2016, 32, 269-280.	1.1	37
39	White matter compromise predicts poor intellectual outcome in survivors of pediatric low-grade glioma. Neuro-Oncology, 2015, 17, 604-613.	1.2	36
40	Distinctive clinical course and pattern of relapse in adolescents with medulloblastoma. International Journal of Radiation Oncology Biology Physics, 2006, 64, 402-407.	0.8	35
41	A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours. European Journal of Cancer, 2009, 45, 2352-2359.	2.8	34
42	EZH2 expression is a prognostic factor in childhood intracranial ependymoma: A Canadian Pediatric Brain Tumor Consortium study. Cancer, 2015, 121, 1499-1507.	4.1	30
43	Atypical Teratoid Rhabdoid Tumors (ATRTs): The British Columbia's Children's Hospital's Experience, 1986â€“2006. Brain Pathology, 2012, 22, 625-635.	4.1	29
44	Neurocognitive evaluation of long term survivors of atypical teratoid rhabdoid tumors (ATRT): The Canadian registry experience. Pediatric Blood and Cancer, 2015, 62, 1265-1269.	1.5	29
45	Opsoclonus-Myoclonus Syndrome: A New Era of Improved Prognosis?. Pediatric Neurology, 2017, 72, 65-69.	2.1	29
46	Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas. Science Translational Medicine, 2021, 13, eabc0497.	12.4	29
47	Leptomeningeal dissemination at diagnosis of pediatric low-grade neuroepithelial tumors. Neuro-Oncology, 2003, 5, 188-196.	1.2	27
48	Optic pathway gliomas in adolescence--time to challenge treatment choices?. Neuro-Oncology, 2013, 15, 391-400.	1.2	27
49	Episodic ataxia associated with a de novo SCN2A mutation. European Journal of Paediatric Neurology, 2016, 20, 772-776.	1.6	26
50	Novel Mutations in FA2H-Associated Neurodegeneration. Journal of Child Neurology, 2013, 28, 1500-1504.	1.4	25
51	Childhood craniopharyngioma: Vancouver experience. Child's Nervous System, 2005, 21, 758-765.	1.1	24
52	Malaysian Siblings with Friedreich Ataxia and Chorea: A Novel Deletion in the Frataxin Gene. Canadian Journal of Neurological Sciences, 2004, 31, 383-386.	0.5	23
53	Intracranial tumors in infants: long-term functional outcome, survival, and its predictors. Child's Nervous System, 2012, 28, 547-555.	1.1	21
54	Deâ€escalation of therapy for pediatric medulloblastoma: Tradeâ€offs between quality of life and survival. Pediatric Blood and Cancer, 2014, 61, 1300-1304.	1.5	21

#	Article	IF	Citations
55	Multimodality therapy for CNS mixed malignant germ cell tumors (MMGCT): results of a phase II multi-institutional study. Journal of Neuro-Oncology, 2014, 118, 93-100.	2.9	21
56	Intracranial growing teratoma syndrome (iGTS): an international case series and review of the literature. Journal of Neuro-Oncology, 2020, 147, 721-730.	2.9	21
57	The role of resection alone in select children with intracranial ependymoma: the Canadian Pediatric Brain Tumour Consortium experience. Child's Nervous System, 2015, 31, 57-65.	1.1	19
58	Determinants of quality of life outcomes for survivors of pediatric brain tumors. Pediatric Blood and Cancer, 2017, 64, e26481.	1.5	18
59	Pleomorphic xanthoastrocytoma of the spinal cord: case report and literature review. , 2014, 33, 190-196.		17
60	Ophthalmological outcomes of patients treated for pineal region tumors. Journal of Neurosurgery: Pediatrics, 2016, 17, 558-563.	1.3	17
61	Trametinib therapy for children with neurofibromatosis type 1 and lifeâ€threatening plexiform neurofibroma or treatmentâ€refractory lowâ€grade glioma. Cancer Medicine, 2021, 10, 3556-3564.	2.8	17
62	Narcolepsy and Hypothalamic Region Tumors: Presentation and Evolution. Pediatric Neurology, 2018, 84, 27-31.	2.1	16
63	Early changes in white matter predict intellectual outcome in children treated for posterior fossa tumors. NeuroImage: Clinical, 2018, 20, 697-704.	2.7	15
64	Intracystic interferon-Î± treatment leads to neurotoxicity in craniopharyngioma: case report. Journal of Neurosurgery: Pediatrics, 2015, 16, 301-304.	1.3	14
65	Long term toxicity of intracranial germ cell tumor treatment in adolescents and young adults. Journal of Neuro-Oncology, 2020, 149, 523-532.	2.9	14
66	Growing teratoma syndrome in intracranial non-germinomatous germ cell tumors (iNGGCTs): a risk for secondary malignant transformationâ€”a report of two cases. Child's Nervous System, 2014, 30, 953-957.	1.1	13
67	Determinants of social competence in pediatric brain tumor survivors who participated in an intervention study. Supportive Care in Cancer, 2017, 25, 2891-2898.	2.2	13
68	Canadian Pediatric Neuro-Oncology Standards of Practice. Frontiers in Oncology, 2020, 10, 593192.	2.8	13
69	Eye Findings on Vigabatrin and Taurine Treatment in Two Patients with Succinic Semialdehyde Dehydrogenase Deficiency. Neuropediatrics, 2016, 47, 263-267.	0.6	11
70	Canadian patterns of practice for intracranial germ cell tumors in adolescents and young adults. Journal of Neuro-Oncology, 2019, 143, 289-296.	2.9	8
71	Pontine gliomas a 10-year population-based study: a report from The Canadian Paediatric Brain Tumour Consortium (CPBTC). Journal of Neuro-Oncology, 2020, 149, 45-54.	2.9	8
72	Cancer and Tumor-Associated Childhood Stroke: Results From the International Pediatric Stroke Study. Pediatric Neurology, 2020, 111, 59-65.	2.1	7

#	Article	IF	Citations
73	Reye syndrome associated with subclinical varicella zoster virus and influenza a infection. Pediatric Neurology, 1993, 9, 134-136.	2.1	6
74	Occurrence of Basal Ganglia Germ Cell Tumors Without a Mass. Archives of Neurology, 2009, 66, 789-92.	4.5	5
75	Lowâ€grade diffusely infiltrative tumour (LGDIT), SMARCB1â€mutant: A clinical and histopathological distinct entity showing epigenetic similarity with ATRTâ€MYC. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	5
76	Multiâ€institutional analysis of treatment modalities in basal ganglia and thalamic germinoma. Pediatric Blood and Cancer, 2021, 68, e29172.	1.5	3
77	Asynchronous burst-suppression in a child with callosal Ki-1 anaplastic large cell lymphoma. Neurology, 2005, 65, 947-949.	1.1	2
78	Assessing the accuracy of death records and pre-mortem clinical diagnoses in children diagnosed with brain tumors: A retrospective chart review of children in British Columbia, Canada. Pathology Research and Practice, 2015, 211, 748-753.	2.3	2
79	IMMU-08. PHASE I TRIAL (NCT02457845) SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF IMMUNOVIROTHERAPY WITH HSV G207 IN CHILDREN WITH PROGRESSIVE MALIGNANT SUPRATENTORIAL BRAIN TUMORS. Neuro-Oncology, 2018, 20, i100-i100.	1.2	2
80	Pontine Embryonal Tumor With Multilayered Rosettes: An Autopsy Case Exhibiting Extensive Posttreatment Glial and Neuronal Maturation. Pediatric and Developmental Pathology, 2020, 23, 326-331.	1.0	2
81	Histologic Correlates of Molecular Group 4 Pediatric Medulloblastoma: A Retrospective Canadian Review. Pediatric and Developmental Pathology, 2021, 24, 309-317.	1.0	2
82	Weekly vinblastine in chemotherapy-naive children with unresectable or progressive low grade glioma: A Canadian cooperative study.. Journal of Clinical Oncology, 2013, 31, 10029-10029.	1.6	2
83	Treatment-responsive Holmes tremor in a child with low-pressure hydrocephalus: video case report and systematic review of the literature. Journal of Neurosurgery: Pediatrics, 2022, 29, 520-527.	1.3	2
84	NFB-08. TRAM-01: A Phase 2 study of trametinib for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas. Neuro-Oncology, 2022, 24, i129-i129.	1.2	2
85	A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway.. Journal of Clinical Oncology, 2022, 40, 2042-2042.	1.6	2
86	A case series of pediatric survivors of anaplastic pleomorphic xanthoastrocytoma. Neuro-Oncology Advances, 2021, 3, vdaa176.	0.7	1
87	Outcome of neurofibromatosis type 1 patients treated with first line vinblastine for optic pathway gliomas: A Canadian multicenter study.. Journal of Clinical Oncology, 2015, 33, 2019-2019.	1.6	1
88	Atypical Presentation of Basal Ganglia Germ Cell Tumors in Children. Journal of Neurosurgery: Pediatrics, 2008, 1, A353-A353.	1.3	1
89	LGG-25. A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. TRAM-01. Neuro-Oncology, 2020, 22, iii371-iii371.	1.2	1
90	CTNI-06. TRAM-01: A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. Neuro-Oncology, 2021, 23, vi59-vi60.	1.2	1

#	Article	IF	Citations
91	Acute Swelling of the Cerebellum in Childhood. Journal of Child Neurology, 1997, 12, 273-275.	1.4	0
92	Epidemiology of malignant pontine gliomas (MPG) in the paediatric population in Canada: A study of the Canadian paediatric brain tumour consortium (CPBTC). Canadian Journal of Neurological Sciences, 2014, 41, S16-S16.	0.5	0
93	AT-07 * SUCCESSFUL TREATMENT OF ATRT PATIENTS WITHOUT ADJUVANT RADIATION: A MULTI INSTITUTIONAL CANADIAN EXPERIENCE. Neuro-Oncology, 2015, 17, iii2-iii2.	1.2	0
94	MB-91OUTCOMES FOR YOUNG CHILDREN WITH BRAIN TUMOURS TREATED ACCORDING TO THE HEAD START PROTOCOLS: A SINGLE-CENTRE EXPERIENCE. Neuro-Oncology, 2016, 18, iii117.4-iii118.	1.2	0
95	GERM-23. INTRACRANIAL GROWING TERATOMA SYNDROME (IGTS): AN INTERNATIONAL RETROSPECTIVE STUDY. Neuro-Oncology, 2018, 20, i88-i88.	1.2	0
96	Canadian Patterns of Practice for Intracranial Germ Cell Tumors in Adolescents and Young Adults. International Journal of Radiation Oncology Biology Physics, 2018, 101, 1009.	0.8	0
97	Factors influencing cognitive outcome in opsoclonusâ€“myoclonus syndrome. Developmental Medicine and Child Neurology, 2020, 62, 1349-1349.	2.1	0
98	Supratentorial Primitive Neuroectodermal Tumors. , 2012, , 15-24.		0
99	Pharmacogenomics of vincristineâ€induced neurotoxicity in pediatric cancer patients. FASEB Journal, 2013, 27, 666.3.	0.5	0
100	NFB-12. TRAMETINIB THERAPY FOR PEDIATRIC PATIENTS WITH REFRACTORY LOW GRADE GLIOMA OR EXTENSIVE SYMPTOMATIC PLEXIFORM NEUROFIBROMA. Neuro-Oncology, 2020, 22, iii420-iii420.	1.2	0
101	HGG-35. PEDIATRIC PLEOMORPHIC XANTHOASTROCYTOMA WITH ANAPLASIA TREATED WITH SURGERY AND ADJUVANT CHEMOTHERAPY: A CASE SERIES OF 3 LONG-TERM SURVIVORS. Neuro-Oncology, 2020, 22, iii350-iii350.	1.2	0
102	LGG-19. SPINAL LOW-GRADE GLIOMAS IN CANADIAN CHILDREN: A MULTI-CENTRE RETROSPECTIVE REVIEW. Neuro-Oncology, 2020, 22, iii369-iii370.	1.2	0
103	GCT-23. MULTI-INSTITUTIONAL ANALYSIS OF TREATMENT MODALITIES IN BASAL GANGLIA AND THALAMIC GERMINOMA. Neuro-Oncology, 2020, 22, iii332-iii332.	1.2	0
104	ATRT-07. Low-grade diffusely infiltrative tumor, SMARCB1-mutant: a clinical and histopathological distinct entity showing epigenetic similarity with ATRT-MYC. Neuro-Oncology, 2022, 24, i3-i4.	1.2	0
105	MEDB-49. Relapsed SHH medulloblastomas in young children. Are there alternatives to full-dose craniospinal irradiation?. Neuro-Oncology, 2022, 24, i117-i117.	1.2	0